Ezrin-radixin-moesin-binding phosphoprotein-50 regulates EGF-induced AKT activation through interaction with EGFR and PTEN

Zheng,Junfang; Dai,Yuanping; Yang,Zhiyu; Yang,Longyan; Peng,Zhiqiang; Meng,Ran; Xiong,Ying; He,Junqi

doi:10.3892/or.2015.4375

Ezrin-radixin-moesin-binding phosphoprotein-50 regulates EGF-induced AKT activation through interaction with EGFR and PTEN

Authors:
- Junfang Zheng
- Yuanping Dai
- Zhiyu Yang
- Longyan Yang
- Zhiqiang Peng
- Ran Meng
- Ying Xiong
- Junqi He
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, P.R. China
Published online on: November 2, 2015 https://doi.org/10.3892/or.2015.4375
Pages: 530-537

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulated epidermal growth factor receptor (EGFR) signaling, especially EGFR/AKT signaling, plays important roles in tumorigenesis and progression, the study on intracellular regulation of this signaling pathway has great clinical significance. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is an important antagonist of AKT activity. Its regulation of AKT activity can be enhanced by ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50)-mediated PTEN/EBP50/platelet-derived growth factor receptor (PDGFR) complex. EBP50 was reported to bind to EGFR, and that it may also mediate the formation of PTEN/EGFR complex to regulate EGFR/AKT signaling. In this study, experiments were performed to verify the hypothesis. Results showed that PTEN co-immunoprecipitated with EGFR, demonstrating PTEN/EGFR complex can form in tissue. Further studies showed that EBP50 knockdown decreased the amount of PTEN/EGFR complex by GST pull-down assay, and EBP50 overexpression increased the amount of PTEN/EGFR complex in a dose-dependent manner. While PTEN mutant (V403A), which can not bind with EBP50, only slightly mediated the formation of PTEN/EGFR complex, confirming that EBP50 specifically mediated the formation of the PTEN/EGFR complex. Both PTEN (V403A) and EGFR (L1043/1063F) mutants can not bind with EBP50. The expression of PTEN (V403A) or EGFR (L1043/1063F) mutant in cells resulted in higher AKT activation level than their respective wild-types by EGF stimulation, indicating that EBP50-mediated PTEN/EGFR complex can effectively inhibit EGF-induced AKT activation. EGF stimulation of siEBP50 cells induced higher AKT activation level compared with control cells, further confirming EBP50-mediated PTEN/EGFR complex can more effectively inhibit EGF-induced AKT activation. These results demonstrated the PTEN/EGFR complex formed under the mediation of EBP50, revealing a novel mechanism for negative regulation of EGF-induced AKT pathway, which may be an important molecular target for antineoplastic therapy.

View Figures

View References

1	Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y and Farajnia S: Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action. Pharmacol Res. 93:1–10. 2015. View Article : Google Scholar
2	Jones S and Rappoport JZ: Interdependent epidermal growth factor receptor signalling and trafficking. Int J Biochem Cell Biol. 51:23–28. 2014. View Article : Google Scholar : PubMed/NCBI
3	Pan D and Lin X: Epithelial growth factor receptor-activated nuclear factor κB signaling and its role in epithelial growth factor receptor-associated tumors. Cancer J. 19:461–467. 2013. View Article : Google Scholar : PubMed/NCBI
4	Han W and Lo HW: Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 318:124–134. 2012. View Article : Google Scholar : PubMed/NCBI
5	Liu R, Gu J, Jiang P, Zheng Y, Liu X, Jiang X, Huang E, Xiong S, Xu F, Liu G, et al: DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res. 21:854–863. 2015. View Article : Google Scholar
6	Khabele D, Kabir SM, Dong Y, Lee E, Rice VM and Son DS: Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF. J Cancer. 5:670–678. 2014. View Article : Google Scholar : PubMed/NCBI
7	Liu G, Jiang C, Li D, Wang R and Wang W: miRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 35:9801–9806. 2014. View Article : Google Scholar : PubMed/NCBI
8	Pei J, Lou Y, Zhong R and Han B: MMP9 activation triggered by epidermal growth factor induced Foxo1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 35:6673–6678. 2014. View Article : Google Scholar : PubMed/NCBI
9	Wang XJ, Feng CW and Li M: ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 380:57–66. 2013. View Article : Google Scholar : PubMed/NCBI
10	Liu W, Ren H, Ren J, Yin T, Hu B, Xie S, Dai Y, Wu W, Xiao Z, Yang X, et al: The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma. Mediators Inflamm. 2013:6512072013. View Article : Google Scholar : PubMed/NCBI
11	Tiganis T, Kemp BE and Tonks NK: The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling. J Biol Chem. 274:27768–27775. 1999. View Article : Google Scholar : PubMed/NCBI
12	Scharl M, Rudenko I and McCole DF: Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion. Am J Physiol Gastrointest Liver Physiol. 299:G935–G945. 2010. View Article : Google Scholar : PubMed/NCBI
13	Omerovic J, Clague MJ and Prior IA: Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells. Biochem J. 426:65–72. 2010. View Article : Google Scholar
14	Takahashi Y, Morales FC, Kreimann EL and Georgescu MM: PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J. 25:910–920. 2006. View Article : Google Scholar : PubMed/NCBI
15	Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkowitz RJ and Hall RA: Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell Biol. 20:8352–8363. 2000. View Article : Google Scholar : PubMed/NCBI
16	Yang L, Wang Y, Chen P, Hu J, Xiong Y, Feng D, Liu H, Zhang H, Yang H and He J: Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) is required for the estradiol-dependent increase of phosphatase and tensin homolog (PTEN) protein expression. Endocrinology. 152:4537–4549. 2011. View Article : Google Scholar : PubMed/NCBI
17	Pan Y, Weinman EJ and Dai JL: Na⁺/H⁺ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res. 10:R52008. View Article : Google Scholar
18	Cheng S, Li Y, Yang Y, Feng D, Yang L, Ma Q, Zheng S, Meng R, Wang S, Wang S, et al: Breast cancer-derived K172N, D301V mutations abolish Na⁺/H⁺ exchanger regulatory factor 1 inhibition of platelet-derived growth factor receptor signaling. FEBS Lett. 587:3289–3295. 2013. View Article : Google Scholar : PubMed/NCBI
19	Rodriguez S and Huynh-Do U: Phosphatase and tensin homolog regulates stability and activity of EphB1 receptor. FASEB J. 27:632–644. 2013. View Article : Google Scholar
20	Yao W, Feng D, Bian W, Yang L, Li Y, Yang Z, Xiong Y, Zheng J, Zhai R and He J: EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation. Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lazar CS, Cresson CM, Lauffenburger DA and Gill GN: The Na⁺/H⁺ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell. 15:5470–5480. 2004. View Article : Google Scholar : PubMed/NCBI
22	Zheng J, Shen H, Xiong Y, Yang X and He J: The beta1-adrenergic receptor mediates extracellular signal-regulated kinase activation via Galphas. Amino Acids. 38:75–84. 2010. View Article : Google Scholar
23	Zheng JF, Sun LC, Liu H, Huang Y, Li Y and He J: EBP50 exerts tumor suppressor activity by promoting cell apoptosis and retarding extracellular signal-regulated kinase activity. Amino Acids. 38:1261–1268. 2010. View Article : Google Scholar
24	Sun C, Zheng J, Cheng S, Feng D and He J: EBP50 phosphorylation by Cdc2/cyclin B kinase affects actin cytoskeleton reorganization and regulates functions of human breast cancer cell line MDA-MB-231. Mol Cells. 36:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
25	Yang X, Zheng J, Xiong Y, Shen H, Sun L, Huang Y, Sun C, Li Y and He J: Beta-2 adrenergic receptor mediated ERK activation is regulated by interaction with MAGI-3. FEBS Lett. 584:2207–2212. 2010. View Article : Google Scholar : PubMed/NCBI
26	He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T and Eng C: Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity. Cancer Res. 73:3029–3040. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xu J, Li Z, Wang J, Chen H and Fang JY: Combined PTEN mutation and protein expression associate with overall and disease-free survival of glioblastoma patients. Transl oncol. 7:196–205.e1. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhang SJ, Endo S, Ichikawa T, Yoshimura J, Onda K, Tanaka R, Washiyama K and Kumanishi T: Rare-type mutations of MMAC1 tumor suppressor gene in human glioma cell lines and their tumors of origin. Jpn J Cancer Res. 90:934–941. 1999. View Article : Google Scholar : PubMed/NCBI
29	Valiente M, Andrés-Pons A, Gomar B, Torres J, Gil A, Tapparel C, Antonarakis SE and Pulido R: Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphory-lation by microtubule-associated serine/threonine kinases. J Biol Chem. 280:28936–28943. 2005. View Article : Google Scholar : PubMed/NCBI
30	Xu D, Yao Y, Jiang X, Lu L and Dai W: Regulation of PTEN stability and activity by Plk3. J Biol Chem. 285:39935–39942. 2010. View Article : Google Scholar : PubMed/NCBI
31	Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, Berchuck A and Futreal PA: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 58:2500–2503. 1998.PubMed/NCBI
32	Barton S, Starling N and Swanton C: Predictive molecular markers of response to epidermal growth factor receptor (EGFR) family-targeted therapies. Curr Cancer Drug Targets. 10:799–812. 2010. View Article : Google Scholar : PubMed/NCBI
33	Suzuki T, Fujii A, Ohya J, Amano Y, Kitano Y, Abe D and Nakamura H: Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci. 98:1977–1984. 2007. View Article : Google Scholar : PubMed/NCBI
34	Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB and Arteaga CL: Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 66:6990–6997. 2006. View Article : Google Scholar : PubMed/NCBI
35	Choura M, Frikha F, Kharrat N, Aifa S and Rebaï A: Investigating the function of three non-synonymous SNPs in EGFR gene: Structural modelling and association with breast cancer. Protein J. 29:50–54. 2010. View Article : Google Scholar : PubMed/NCBI
36	Ueno S, Sudo T, Oka N, Wakahashi S, Yamaguchi S, Fujiwara K, Mikami Y and Nishimura R: Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma. Int J Gynecol Cancer. 23:1084–1091. 2013. View Article : Google Scholar : PubMed/NCBI
37	Georgescu MM, Morales FC, Molina JR and Hayashi Y: Roles of NHERF1/EBP50 in cancer. Curr Mol Med. 8:459–468. 2008. View Article : Google Scholar : PubMed/NCBI
38	Shibata T, Chuma M, Kokubu A, Sakamoto M and Hirohashi S: EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology. 38:178–186. 2003. View Article : Google Scholar : PubMed/NCBI